secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADIAL PHARMACEUTICALS, INC. (ADIL)
CIK:        0001513525
Form:       8-K
Filed at:   2023-11-14T23:59:59+00:00
Accession:  0001213900-23-087129
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adial Pharma Q3 net loss narrows to $1.4M; $4M private placement extends runway into Q4 2024
--------------------------------------------------------------------------------

- Net loss $1.4M in Q3 2023, down 55% from $3.1M in Q3 2022.
- R&D expenses decreased $489K (70%) YoY as AD04 trial activities wound down.
- G&A expenses decreased $708K (38%) YoY due to lower compensation and headcount.
- Cash $315K at Sep 30; $4M private placement (net $3.5M) completed post-quarter extends runway into Q4 2024.
- Planning two parallel Phase 3 trials for AD04; in confidentiality agreements with potential partners.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1513525/000121390023087129/0001213900-23-087129-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1513525/000121390023087129/ea188439-8k_adialpharma.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-087129

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer